Charles Schwab Investment Management Inc. Has $14.81 Million Position in Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Charles Schwab Investment Management Inc. increased its position in AMNEAL PHARMACEUTICALS by 14.8%, owning approximately 1.77 million shares valued at $14.81 million at the end of the most recent quarter.
• Other institutional investors like Janney Montgomery Scott LLC and Allspring Global Investments made significant increases to their stakes in AMNEAL PHARMACEUTICALS, highlighting growing interest in the stock.
• AMNEAL PHARMACEUTICALS reported a 0.23 EPS for the last quarter, exceeding estimates, and set its FY 2025 guidance at 0.700-0.750 EPS.

Charles Schwab Investment Management Inc. lifted its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 14.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,767,594 shares of the company's stock after acquiring an additional 227,660 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.57% of Amneal Pharmaceuticals worth $14,812,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of AMRX. GAMMA Investing LLC grew its stake in shares of Amneal Pharmaceuticals by 5,975.0% in the first quarter. GAMMA Investing LLC now owns 3,159 shares of the company's stock worth $26,000 after acquiring an additional 3,107 shares during the last quarter. Amalgamated Bank grew its stake in shares of Amneal Pharmaceuticals by 33.0% in the first quarter. Amalgamated Bank now owns 5,511 shares of the company's stock worth $46,000 after acquiring an additional 1,367 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Amneal Pharmaceuticals in the fourth quarter worth $52,000. Brevan Howard Capital Management LP acquired a new stake in shares of Amneal Pharmaceuticals in the fourth quarter worth $107,000. Finally, Xponance Inc. lifted its position in Amneal Pharmaceuticals by 16.1% in the first quarter. Xponance Inc. now owns 13,183 shares of the company's stock worth $110,000 after purchasing an additional 1,828 shares during the period. Institutional investors and hedge funds own 31.82% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on AMRX shares. The Goldman Sachs Group started coverage on Amneal Pharmaceuticals in a research report on Friday, June 6th. They issued a "buy" rating and a $12.00 target price for the company. Wall Street Zen cut Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $11.60.

Insider Buying and Selling

In other news, EVP Andrew S. Boyer sold 279,244 shares of the business's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $9.38, for a total transaction of $2,619,308.72. Following the completion of the transaction, the executive vice president directly owned 152,426 shares in the company, valued at approximately $1,429,755.88. The trade was a 64.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jason B. Daly sold 22,000 shares of the business's stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $9.05, for a total value of $199,100.00. Following the transaction, the executive vice president owned 10,606 shares of the company's stock, valued at $95,984.30. The trade was a 67.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 577,206 shares of company stock worth $5,405,265 over the last three months. 17.45% of the stock is currently owned by company insiders.

Amneal Pharmaceuticals Stock Down 0.2%

Amneal Pharmaceuticals stock traded down $0.02 during mid-day trading on Wednesday, hitting $9.36. 821,888 shares of the company were exchanged, compared to its average volume of 1,676,661. The business has a fifty day moving average of $8.43 and a 200 day moving average of $8.03. Amneal Pharmaceuticals, Inc. has a 1-year low of $6.68 and a 1-year high of $9.79. The company has a market capitalization of $2.94 billion, a PE ratio of 936.94 and a beta of 1.11.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. Research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.